XLRN News and Press, Acceleron Pharma Inc. From 11/04/21

- Acceleron recognized approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL ® (luspatercept-aamt) - - Three clinical abstracts on REBLOZYL have been accepted for presentation at the 63rd American Society o...

Acceleron Pharma (NASDAQ:XLRN) holder Farallon Capital Management doesn't support Merck's $180/share acquisition of the company. Farallon, which is a top-10 Acceleron (XLRN) holder with a more than 4% stake, told Bloomberg in email that the company doesn't support terms of its sale to Merck (...

Baird has initiated Geron (NASDAQ:GERN) with an outperform rating as it has a "strong outlook" on the company's lead agent, imetelstat, for lower risk myelodysplasia and myelofibrosis. The firm has a $4 price target on shares (~155% upside). Phase 3 results on the candidate is expected in Jan...

Shares of Gossamer Bio have rebounded some 75% off their lows set in mid-July and have pivoted away from its failed asthma asset GB001. Merck’s $11 billion overture for Acceleron and its PAH candidate (sotatercept), in addition to positive commentary from Piper have also booste...

Merck has withdrawn its Premerger Notification and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act to provide the Federal Trade Commission with additional time for review its proposed acquisition of Acceleron Pharma (NASDAQ:XLRN). In September, Merck, through a subsidiary, ...

NEW YORK, NY / ACCESSWIRE / October 28, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Columbia Property Trust, Inc. (NYSE:CXP) concerning potential violations of the federal securities laws and/or breaches of fiduciary...

Remains Opposed to Sale of Acceleron to Merck at Current Price and Plans Not to Tender Its Shares Believes Company Has Strong Momentum and Continuing as Standalone Entity is Superior Path to a Transaction at the Proposed Price, Particularly with Major Value Inflection Point Co...

Merck (NYSE:MRK) is trading ~1.2% higher in the pre-market after the company reported better-than-expected financials for Q3 2021. The pharma giant raised and narrowed its 2021 revenue and non-GAAP EPS projection to $47.4B – $47.9B and $5.65 – $5.70, falling short...

- Acceleron expects to report approximately $32.0 million in royalty revenue for Q3 2021 from approximately $160 million in net sales of REBLOZYL ® (luspatercept-aamt) as reported by Bristol Myers Squibb – Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceuti...

NEW YORK, NY / ACCESSWIRE / October 23, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Aspen Technology, Inc. (NASDAQ:AZPN) concerning potential violations of the federal securities laws and/or breaches of fiduciary dut...